We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday. “We’re not alarmed at all ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche raised hopes this year that it had a future blockbuster drug on its hands after early trial results ...

FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine. The poster, released as part ...

In a meeting of the European Association for the Study of Diabetes that day, Roche presented the results of an early-stage clinical trial of its CT-996 pill. This is the Switzerland-based company ...

Roche shares fall 3.5% Early study trial showed high rate of temporary side effects JP Morgan analysts say heart rate increase is as a concern Roche plans slower ramp-up of pill dose in next trial ...

Shares of Roche (OTCQX:RHHBY) slid 5% Wednesday while shares of rivals Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) gained ground after Reuters reported that positive data released by Roche (OTCQX ...